Hormone receptor–positive and ERBB2-negative breast cancer is the most common subtype, while HR-negative and ERBB2-positive breast cancer is the rarest.3 Subtypes also vary in their clinical aggressiveness and treatability, with HR-negative and ERBB2-negative breast cancer being the most lethal and difficult to treat.4 This evidence concerns the gene ERBB2 and breast carcinoma.